MX2017013176A - Composiciones y metodos para tratar autismo. - Google Patents

Composiciones y metodos para tratar autismo.

Info

Publication number
MX2017013176A
MX2017013176A MX2017013176A MX2017013176A MX2017013176A MX 2017013176 A MX2017013176 A MX 2017013176A MX 2017013176 A MX2017013176 A MX 2017013176A MX 2017013176 A MX2017013176 A MX 2017013176A MX 2017013176 A MX2017013176 A MX 2017013176A
Authority
MX
Mexico
Prior art keywords
disease
compositions
syndrome
treating intestinal
intestinal hyperpermeability
Prior art date
Application number
MX2017013176A
Other languages
English (en)
Inventor
Hoffman Steven
Original Assignee
Hoffman Steven
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US14/686,545 external-priority patent/US9308188B2/en
Priority claimed from US15/059,602 external-priority patent/US9763903B2/en
Application filed by Hoffman Steven filed Critical Hoffman Steven
Publication of MX2017013176A publication Critical patent/MX2017013176A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)

Abstract

La presente invención proporciona métodos, composiciones, y kits o equipos para tratar hiperpermeabilidad intestinal en un sujeto que lo necesita, incluyendo condiciones tal como hiperglicemia y trastornos subyacentes tal como diabetes, autismo, fibromialgia, trastorno de intestino inflamatorio (IBD), trastorno de injerto versus hospedador (GVHD), VIH/SIDA, síndrome de disfunción de múltiples órganos, síndrome de intestino irritable (IBS), trastorno celiaco, eccema, psoriasis, pancreatitis aguda, enfermedad de Parkinson, depresión, síndrome de fatiga crónica, asma, esclerosis múltiple, artritis, espondilitis anquilosante, trastorno de hígado graso no alcohólico, cirrosis alcohólica, enteropatía ambiental, o kwashiorkor.
MX2017013176A 2015-04-14 2016-03-28 Composiciones y metodos para tratar autismo. MX2017013176A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14/686,545 US9308188B2 (en) 2013-10-22 2015-04-14 Compositions and methods for treating intestinal hyperpermeability
US15/059,602 US9763903B2 (en) 2013-10-22 2016-03-03 Compositions and methods for treating intestinal hyperpermeability
PCT/US2016/024432 WO2016167944A2 (en) 2015-04-14 2016-03-28 Compositions and methods for treating intestinal hyperpermeability

Publications (1)

Publication Number Publication Date
MX2017013176A true MX2017013176A (es) 2018-01-30

Family

ID=57126753

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017013176A MX2017013176A (es) 2015-04-14 2016-03-28 Composiciones y metodos para tratar autismo.

Country Status (12)

Country Link
EP (2) EP3283115B1 (es)
JP (1) JP6858131B2 (es)
KR (1) KR20180015126A (es)
CN (1) CN107835695B (es)
AU (1) AU2016247301A1 (es)
BR (1) BR112017022184A2 (es)
CA (1) CA2982442A1 (es)
EA (1) EA038339B1 (es)
IL (1) IL254963A0 (es)
MX (1) MX2017013176A (es)
PH (1) PH12017501864A1 (es)
WO (1) WO2016167944A2 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10813901B2 (en) 2013-10-22 2020-10-27 Yamo Pharmaceuticals Llc Compositions and methods for treating autism
US10751313B2 (en) 2013-10-22 2020-08-25 Yamo Pharmaceuticals Llc Compositions and methods for treating autism
WO2020018292A1 (en) * 2018-07-19 2020-01-23 Yamo Pharmaceuticals Llc Compositions and methods for treating autism
CN112789045A (zh) 2018-07-19 2021-05-11 亚莫制药有限公司 用于治疗孤独症的组合物和方法
KR102726917B1 (ko) 2019-02-01 2024-11-07 닥터레이몬드 랩(주) 자폐증의 예측방법
WO2020232227A1 (en) 2019-05-14 2020-11-19 Tyme, Inc. Compositions and methods for treating cancer
US10905698B1 (en) 2020-05-14 2021-02-02 Tyme, Inc. Methods of treating SARS-COV-2 infections

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4165382A (en) * 1977-10-17 1979-08-21 Jose Pozuelo Method of pharmacologically treating schizophrenia with alpha-methyl-para-tyrosine
US6498247B2 (en) * 2000-04-13 2002-12-24 Pro-Health, Inc. Alkali or alkaline earth metal of n-butyric acid for treatment of cognitive and emotional conditions
US20060088607A1 (en) * 2004-10-01 2006-04-27 Stefano George B Nutritional supplement compositions
WO2012123819A1 (en) * 2011-03-15 2012-09-20 Optinose As Et Al Nasal delivery
PL220308B1 (pl) * 2011-06-03 2015-10-30 Kobel Buys Krystyna Zastosowanie klenbuterolu do leczenia objawów autyzmu dziecięcego oraz klenbuterol do zastosowania w leczeniu objawów autyzmu dziecięcego
WO2013103746A1 (en) * 2012-01-03 2013-07-11 Curemark, Llc Methods of treating behavioral symptoms of neurological and mental disorders
US20130183263A1 (en) * 2012-01-17 2013-07-18 Steven Hoffman Pharmaceutical compositions and methods
US20150111878A1 (en) * 2013-10-22 2015-04-23 Steven Hoffman Compositions and methods for treating intestinal hyperpermeability
US9326962B2 (en) * 2013-10-22 2016-05-03 Steven Hoffman Compositions and methods for treating intestinal hyperpermeability

Also Published As

Publication number Publication date
CA2982442A1 (en) 2016-10-20
IL254963A0 (en) 2017-12-31
JP6858131B2 (ja) 2021-04-14
EP4438059A2 (en) 2024-10-02
CN107835695B (zh) 2021-07-09
JP2018511639A (ja) 2018-04-26
WO2016167944A3 (en) 2017-08-10
KR20180015126A (ko) 2018-02-12
EP3283115A2 (en) 2018-02-21
EP4438059A3 (en) 2025-01-01
PH12017501864A1 (en) 2018-03-05
EP3283115C0 (en) 2024-06-12
CN107835695A (zh) 2018-03-23
WO2016167944A8 (en) 2017-11-02
EA038339B1 (ru) 2021-08-11
AU2016247301A1 (en) 2017-10-26
EA201792278A1 (ru) 2018-04-30
BR112017022184A2 (pt) 2018-07-03
WO2016167944A2 (en) 2016-10-20
EP3283115B1 (en) 2024-06-12

Similar Documents

Publication Publication Date Title
PH12020550046A1 (en) Tyrosine hydroxylase inhibitors for treating intestinal hyperpermeability
MX2017013176A (es) Composiciones y metodos para tratar autismo.
BR112018074979A2 (pt) composições de limpeza que compreendem enzimas
ZA202001294B (en) Multispecific antibody
AR106801A1 (es) Composiciones que comprenden cepas bacterianas
WO2016130806A3 (en) Patatin-like phospholipase domain containing 3 (pnpla3) irna compositions and methods of use thereof
MX2018013224A (es) Número de objetivo por amplificación de discordancias optimizada multiplicada (moma).
JO3686B1 (ar) جلوكان ومركبات مساعِدات glp-1 مشتركة
EP3750907A3 (en) Raav-based compositions and methods for treating amyotrophic lateral sclerosis
HK1244843A1 (zh) 载脂蛋白c3(apoc3)irna组合物及其使用方法
EP4282974A3 (en) Linked duplex target capture
EP4368728A3 (en) Simultaneous quantification of gene expression in a user-defined region of a cross-sectioned tissue
MX394473B (es) Composiciones farmaceuticas que comprenden glitazonas y activadores de nrf2.
EP4467654A3 (en) Genome fractioning
WO2015112896A3 (en) Methods and compositions for sequences guiding cas9 targeting
JO3558B1 (ar) تركيبات وطرق لتثبيط التعبير الجيني عن hao1 (حمض أوكسيداز هيدروكسيلي 1 (أوكسيداز جليكولات))
GB2540702A (en) Nucleic acid processing of a nucleic acid fragment with a triazole linkage
BR112013002202A2 (pt) (met)acrilato de polialquila para melhorar as propriedades de óleos lubrificantes
MX2017005219A (es) Composiciones de curado anaerobio que tienen esteres vinilicos novolac.
MX2019003890A (es) Anticuerpos con union reducida a impurezas de proceso.
WO2014210199A3 (en) Methods of performing polymerase chain reaction and related uses thereof
EP3149192A4 (en) Methods and compositions for use of neutrophil elastase and proteinase 3 as diagnostic biomarkers
MY198780A (en) Process for the biological production of methacrylic acid and derivatives thereof
PH12020551791A1 (en) Methods for the production of methacrylates
WO2014088830A3 (en) Screening of nucleic acid agents via particle display